山東金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)醫(yi)藥(yao)(yao)(yao)(yao)集團股份有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)(簡稱(cheng)“金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)醫(yi)藥(yao)(yao)(yao)(yao)”,股票(piao)代碼(ma):300233)成(cheng)立于2004年,創(chuang)業(ye)(ye)(ye)板上市企(qi)業(ye)(ye)(ye)。目前,公(gong)(gong)司(si)(si)(si)(si)(si)擁有(you)(you)(you)北京朗依制藥(yao)(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)、上海(hai)金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)藥(yao)(yao)(yao)(yao)業(ye)(ye)(ye)有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)、廣(guang)東金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)金(jin)(jin)(jin)(jin)素(su)制藥(yao)(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)、山東金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)生物(wu)藥(yao)(yao)(yao)(yao)業(ye)(ye)(ye)有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)、山東金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)醫(yi)藥(yao)(yao)(yao)(yao)化工有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)、山東金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)石墨烯科(ke)技有(you)(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)(si)(si)、意大利海(hai)寶露有(you)(you)(you)限(xian)(xian)責任公(gong)(gong)司(si)(si)(si)(si)(si)等18家參控股公(gong)(gong)司(si)(si)(si)(si)(si)。公(gong)(gong)司(si)(si)(si)(si)(si)通(tong)過“實業(ye)(ye)(ye)+資本”雙輪驅動發展模式,已構建形(xing)成(cheng)獨具(ju)金(jin)(jin)(jin)(jin)城(cheng)(cheng)(cheng)特(te)(te)色的醫(yi)藥(yao)(yao)(yao)(yao)健(jian)康制藥(yao)(yao)(yao)(yao)工業(ye)(ye)(ye)產(chan)業(ye)(ye)(ye)鏈(lian),業(ye)(ye)(ye)務范圍涉及生物(wu)制藥(yao)(yao)(yao)(yao)、頭孢類醫(yi)藥(yao)(yao)(yao)(yao)中(zhong)間體(ti)、特(te)(te)色原料(liao)藥(yao)(yao)(yao)(yao)、終端制劑、保健(jian)品、新材(cai)料(liao)等產(chan)業(ye)(ye)(ye)領域,并現已形(xing)成(cheng)年營業(ye)(ye)(ye)收入超20億(yi)元、總資產(chan)近50億(yi)的產(chan)業(ye)(ye)(ye)規模。
山東金城醫(yi)藥集(ji)團股份有限公司是以(yi)三、四代頭孢類醫(yi)藥中間體(ti)(ti)、特(te)色原(yuan)料藥、生(sheng)物制藥、終(zhong)端制劑以(yi)及婦兒產(chan)品(pin)(pin)(pin)等(deng)為主業(ye)的科研、生(sheng)產(chan)企(qi)業(ye),其中,頭孢類醫(yi)藥中間體(ti)(ti)產(chan)品(pin)(pin)(pin)銷量、銷售收入連續多(duo)年位居(ju)行(xing)業(ye)前列,是重(zhong)要的生(sheng)物制藥生(sheng)產(chan)基地以(yi)及國內醫(yi)藥健康產(chan)業(ye)集(ji)團。主導產(chan)品(pin)(pin)(pin)有谷胱甘(gan)肽(花(hua)青肽美品(pin)(pin)(pin)牌(pai))、硝呋太爾(er)膠囊(朗依品(pin)(pin)(pin)牌(pai))、富馬(ma)酸(suan)比(bi)索洛(luo)爾(er)膠囊(洛(luo)雅品(pin)(pin)(pin)牌(pai))、牡蠣碳酸(suan)鈣咀(ju)嚼片(pian)(pian)(金娃(wa)寧品(pin)(pin)(pin)牌(pai))、復(fu)方木香鋁鎂片(pian)(pian)(德瑞夫品(pin)(pin)(pin)牌(pai))等(deng)近百(bai)種。
當前(qian),公司堅持科(ke)學發(fa)展,按照(zhao)“大(da)(da)健(jian)康、大(da)(da)醫藥(yao),打造(zao)具有金城特色制(zhi)(zhi)藥(yao)產(chan)(chan)業(ye)(ye)鏈”的(de)產(chan)(chan)業(ye)(ye)定位(wei)和“調(diao)整、轉型、升級(ji)、發(fa)展”的(de)戰略思路(lu),專注專注金城特色制(zhi)(zhi)藥(yao)產(chan)(chan)業(ye)(ye)鏈三大(da)(da)方向建設(she)——“頭孢(bao)類抗生素終端制(zhi)(zhi)劑(ji)產(chan)(chan)業(ye)(ye)鏈,多(duo)肽類特色生物制(zhi)(zhi)藥(yao)產(chan)(chan)業(ye)(ye)鏈和婦科(ke)、調(diao)節(jie)免疫制(zhi)(zhi)劑(ji)特色類產(chan)(chan)業(ye)(ye)鏈 ”。同時,公司加(jia)快(kuai)“三個平(ping)臺(tai)(tai)”建設(she)(技術創新平(ping)臺(tai)(tai)、產(chan)(chan)業(ye)(ye)運營平(ping)臺(tai)(tai)、組(zu)織管(guan)控(kong)平(ping)臺(tai)(tai)),加(jia)快(kuai)打造(zao)“四(si)支隊(dui)伍(wu)(wu)”建設(she)(企(qi)業(ye)(ye)家隊(dui)伍(wu)(wu)、中高層管(guan)理隊(dui)伍(wu)(wu)、專業(ye)(ye)人才隊(dui)伍(wu)(wu)、熟練工(gong)人隊(dui)伍(wu)(wu)),積極實踐內涵式(shi)發(fa)展、外(wai)延式(shi)擴(kuo)張和投(tou)資并購三種發(fa)展方式(shi),著力將公司打造(zao)成“科(ke)技化(hua)、生態化(hua)、規范化(hua)、品牌化(hua)、國際化(hua)”的(de)現(xian)代化(hua)醫藥(yao)健(jian)康產(chan)(chan)業(ye)(ye)集團,助推醫藥(yao)進步,創享健(jian)康生活,志在成為(wei)醫藥(yao)健(jian)康產(chan)(chan)業(ye)(ye)創新型領(ling)軍企(qi)業(ye)(ye)。